Search Results

Foreign currency Share based Contributed Equity translation reserve payment reserve Retained earnings Total Consolidated Entity US$m US$m US$m US$m US$m 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 As at the beginning of the year (4,603.0) (4,634.5) (5.7) 29.1 247.7 195.1 9,612.3 8,490.2 5,251.3 4,079.9 Profit for the period - - - - - - 2,102.5 1,918.7 2,102.5 1,918.7 Other comprehensive income - - 13.3 (34.8) - - (13.6) (67.1) (0.3) (101.9) Total comprehensive income for the full year 2,102.2 1,816.8 Transactions with owners in their capacity as owners Opening balance sheet adjustment adopting AASB 16 and 15 (See Accounting Policies disclosure) - - - - - - (65.0) 74.0 (65.0) 74.0 Share based payments - - - - 81.0 52.6 - - 81.0 52.6 Dividends - - - - - - (883.1) (806.8) (883.1) (806.8) Share issues - Employee share scheme 42.0 31.5 - - - - - 42.0 31.5 Other - - - - - - (0.8) 3.3 (0.8) 3.3 As at the end of the year (4,561.0) (4,603.0) 7.6 (5.7) 328.7 247.7 10,752.3 9,612.3 6,527.6 5,251.3

US$1.85 total full year dividend per share.

2000 2015 2017 2020 2022 Swiss company, Novartis' influenza CSL entered the Vitaeris was In August 2022, In December ZLB, was acquired vaccine business cell and gene acquired in CSL completed 2022, CSL in 2000, and was acquired therapy field June 2020, the acquisition finalised a global Aventis Behring in 2015.

CSL KMP in 2024 AGM Annual General Meeting Name Position Term as KMP ARMC Audit and Risk Management Committee CEO Chief Executive Officer and Managing Director NEDs CFO Cashflow from Operations Dr Brian Chair and Independent Full year McNamee AO Non-Executive Director EPS Earnings per Share Dr Megan Independent Full year EPSg Earnings per Share growth Clark AC Non-Executive Director EVP Executive Vice President Professor Andrew Non-Independent Full year Cuthbertson AO Non-Executive Director FR Fixed Reward Ms Carolyn Independent Full year HRRC Human Resources and Remuneration Hewson AO Non-Executive Director Committee Ms Independent Part year - from KMP Key Management Personnel Samantha Lewis Non-Executive Director 1 January 2024 KPI Key Performance Indicator Professor Independent Full year LTI Long Term Incentive Duncan Maskell Non-Executive Director NED Non-Executive Director Ms Marie Independent Full year McDonald Non-Executive Director NPATA Net Profit after Tax and before Amortisation1 Ms Alison Independent Full year PSU Performance Share Unit Watkins AM Non-Executive Director

The approval of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months is based on efficacy and safety data from the INNO 2 VATE program and an assessment of post marketing safety data from Japan where Vafseo was launched in August 2020.

2020.

Removed OM Pharma from the list of Vifor Pharma Group companies in Section 2 Changed the reporting period from 2019 to 2020 in Section 4.3 Transfer of Value Date.

The full year fixed reward for P Perreault was US$1,856,133, the full year cash STI payment was US$2,262,385 and the full year share based payment expense was US$3,654,625.

Income Tax Paid Income tax paid is calculated as the cash tax paid in the year 1 July 2020 - 30 June 2021.

KING OF PRUSSIA, Pa. 29 Oct 2020